UK tech startup, Molecular Warehouse, received funding of £250,000 for a project for a molecular bio-sensing platform that can remotely monitor the levels of drugs needed to prevent organ rejection. The project opens markets for companies investing in bio-sensing technologies.
The company’s application areas, which are at various stages of development, include: diagnosis of acute pancreatitis, haemophilia and coagulation, chronic stress, vitamin D deficiency and prostate cancer.
At Health 2.0, a recent conference on digital health, the Guildford-based company, was singled out from more than 100 contenders as the best candidate for Series A funding.
Intellectual property
Chief executive Dr Siro Perez and his management team are now in the process of raising another £2m from current investors in their Series A campaign, having already attracted crowdfunding of £750,000 in November 2016.
Dr Perez explained: “We have more than 40 companies and a large number of clinicians interested in our technology. The main intellectual property we hold is in the bio-sensors that we have re-engineered to recognise protein biomarkers and drugs – or anything molecular, really. The potential is huge.
“We always had a very ambitious business plan but the grant from Innovate UK helped a lot. It carries a lot of prestige, even with investors from outside the UK. We had raised about £200,000 ourselves. Then we got the grant and, on the back of that, were able to raise £1.2m more.”
Molecular Warehouse, which has grown from 3 staff at the start of the project to 12, has since struck a co-development agreement with Chiesi Pharmaceuticals for the transplant application.
If certain milestones are reached, Chiesi will finance the final clinical development, regulatory approval and commercialisation of the test. It will then become rapidly available to hundreds of thousands of patients globally.
Self-testing at home
The concentration of drugs in a transplant patient’s bloodstream needs to be maintained in a narrow range that lowers the immune system’s reactivity enough to avoid rejection, but does not expose the patient to an increased risk of infections.
Studies indicate that 40% of transplant failures are due to poor monitoring of drug levels and not adhering to medication.
The goal of the collaboration between Chiesi and Molecular Warehouse is to develop a system that will enable patients to self-test at home. That will save time visiting clinics and precious health service resources, and reduce the rate of readmissions to hospital and transplant failures.
Every successful kidney transplant leads to a 10-year increase in patient life expectancy and over £250,000 in cost savings to the NHS compared to the patient being on dialysis.
If used by the 35,000 kidney transplant patients in UK, Molecular Warehouse estimates that its test could save the NHS almost £80m annually and save hundreds of lives.
Following successful tests of the first batch of volume-manufactured sensor chips, Dr Perez expects the monitoring platform to complete regulatory and CE mark approval by April next year, initially for dialysis patients.
The plan is for the device to be in use by health care professionals in the first half of 2018 and to go ‘live’ with patients later in the year.
